Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatologic Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynecologic Cancers
Hematology
Hematologic Malignancies
Head and Neck Cancer
Immunotherapy
Leukemia
Lymphoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Lung Cancer
Prostate Cancer
Renal Cancer
Endocrine Cancers
Pediatric Oncology
Policy
Sarcoma
Supportive Cancer Care
Soft Tissue Tumors
Neuro-oncology
Pathology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic
3 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Foreword – touchREVIEWS in Oncology & Haematology, Volume 22, Issue 2, 2026

Axel S Merseburger

It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue reflects the growing momentum of precision oncology, from liquid biopsy and response-adapted strategies to antibody–drug conjugates (ADCs) and immune-based therapies, alongside the challenges of translating these advances into routine, equitable care. We open with an editorial […]

touchREVIEWS in Oncology & Haematology. 2026;22(2):1

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
touchHUB
CE/CME accredited
Overview

Neurofibromatosis type 1

Discover expert insights into the management of neurofibromatosis type 1 (NF1) across the life course, from childhood through transition to adult care. Explore the management of NF1-associated plexiform neurofibromas, including evolving targeted-treatment options, multidisciplinary management, and patient-centered approaches to assessing symptoms, function and quality of life.

Learning Objectives Skip to Activities

These activities are funded by:

Independent medical education grants from Alexion and SpringWorks Therapeutics, Inc.

These activities are jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

Latest Activities

Downloads

Activities
Downloads
Activity 2

Management of NF1-related PNs: Approaches for delivering state-of-the-art care3

Learning Objectives
Launched Sep 30, 26
11 mins
Module 1 1 Module

When should systemic and targeted therapies be considered for adults with NF1-PNs?

View Chapters
Expert discussion of how symptoms, functional impact, resectability and patient goals can guide treatment decisions for adults with NF1-PNs
A neurosurgeon and an oncologist discuss the role of surgery, MEK inhibitors, and multidisciplinary care in adult NF1-PN management

Activity Modules

Close

Introduction

Duration: 2:46

What do you think is the optimal approach to monitoring adults with NF1-PNs, and what factors would lead you to move from a watch-and-wait approach to active management?

Duration: 1:09

What are some of the key challenges in establishing an optimal approach to treating and managing NF1-PNs in adults, and which clinical specialists do you routinely include in discussions about management options?

Duration: 2:06

When discussing the benefits and risks of targeted therapies for NF1-PNs with adult patients as part of shared decision‑making, what points are particularly important for them to understand?

Duration: 2:18

How long do you typically continue targeted therapy if a patient’s NF1‑PN responds well? If treatment benefit is limited, lost over time, or treatment is stopped, how do you decide what to do next?

Duration: 3:25
9 mins
Module 2

How can adverse effects be monitored and managed to maximize therapeutic benefit?

View Chapters
Expert discussion of baseline assessment, ongoing monitoring, and early management of MEK inhibitor–related adverse effects in adults with NF1-PNs
A neurosurgeon and an oncologist discuss dermatologic, gastrointestinal, ocular, and cardiac considerations during MEK inhibitor treatment

Activity Modules

Close

Introduction

Duration: 1:47

What baseline assessments and on‑treatment monitoring do you recommend for adults with NF1‑PNs receiving a MEK inhibitor, and do these vary according to patient or disease characteristics?

Duration: 1:58

Which MEK inhibitor‑related adverse effects are most important to recognize early in adults with NF1‑PN, and which are most likely to affect treatment adherence or require specialist input?

Duration: 3:10

How do you approach prevention and management of common toxicities, including dermatologic, gastrointestinal, ocular, and cardiac adverse effects, to maximize tolerability and support continuation of treatment?

Duration: 2:38
12 mins
Module 3

How can pain, function and quality of life guide shared decisions in NF1-PN care?

View Chapters
Expert discussion of using pain, function and quality of life to establish patient-centered goals and guide NF1-PN care
A neurosurgeon and an oncologist discuss shared decision-making, multidisciplinary care, and coordination with community providers

Activity Modules

Close

Introduction

Duration: 2:40

Which tools do you routinely use to capture pain, function, and health‑related quality of life in adults with NF1‑PN, and what do you see as their strengths and limitations in informing treatment and management decisions?

Duration: 3:34

Who should be involved in the multidisciplinary care of adults with NF1‑PN, and how does the structure and function of the MDT differ from that in pediatric care?

Duration: 4:44

What barriers exist to delivering optimal care for adults with NF1‑PN in community settings vs specialized NF centers, and what practical steps can clinicians take to address these gaps?

Duration: 1:41
Activity 1

Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life3

Learning Objectives
Launched Jan 07, 25
35 mins
3 Modules

Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life

View Modules

Three experts share insights into the treatment and care of patients with NF1 from childhood to adulthood.

Activity Modules

Close

Navigating treatment options for NF1 in paediatric patients with Dr AeRang Kim

Duration: 12:32

Optimal care for adult patients with NF1 with Dr Rebecca Brown

Duration: 11:25

Best practices for continuity of care for patients with NF1 from childhood to adulthood with Dr Kaleb Yohay

Duration: 12:06
Activity 2

Management of NF1-related PNs: Approaches for delivering state-of-the-art care

Launched Sep 30, 26

English Downloads

Download Slides

File Type: PDF
File Size: 0.74 MB
Download

Download Practice Aid

File Type: PDF
File Size: 0.7 MB
Download
Activity 1

Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life3

Launched Jan 07, 25

Download Slides

File Type: PDF
File Size: 0.6 MB
Download

Download Practice Aid

File Type: PDF
File Size: 0.75 MB
Download

Expert Faculty5

Learn directly from experts in the field of Neuro-oncology and Rare Diseases

Dr AeRang Kim

Children's National Hospital, Washington, DC, USA
More Information
Close Popup

Dr AeRang Kim

Children's National Hospital, Washington, DC, USA

Biography

Dr AeRang Kim is a professor of paediatrics with tenure and the director of clinical research in the Division of Oncology and Solid Tumors attending at Children’s National Hospital in Washington, DC.

read more

Dr Kim’s research focuses on novel therapeutics for paediatric solid tumours, sarcomas and NF1-associated tumours, in particular malignant peripheral nerve sheath tumours (MPNST).

Dr Kim serves as the MPNST disease committee chair for the Department of Defense Clinical Trials Consortium. She is the co-director of the Focused Ultrasound Foundation Center of Excellence at the Children’s National Hospital. With collaborators and federal funding support, Dr AeRang Kim has been able to develop and lead early-phase trials of novel combination therapeutics for paediatric patients with solid tumours, including sarcoma. She also serves as the institutional principal investigator at Children’s National Hospital for the Children’s Oncology Group, Pediatric Early Phase Clinical Trials Network with the major goal of conducting early-phase trials in children with cancer to identify and develop new agents for children and adolescents.

Dr AeRang Kim has no financial interests/relationships or affiliations to disclose in relation to this activity.

Dr. Angela Hirbe

Dr Rebecca Brown

Dr Rebecca Brown

University of Alabama School of Medicine, Birmingham, AL, USA
More Information
Close Popup

Dr Rebecca Brown

University of Alabama School of Medicine, Birmingham, AL, USA

Biography

Dr Rebecca Brown, MD, PhD is the director of the neurofibromatosis programme at the University of Alabama at Birmingham (UAB).

read more

Dr Brown is a board-certified neuro-oncologist and neurologist who specializes in neurofibromatosis (NF) and schwannomatosis (SWN; including NF2-related schwannomatosis), and related genetic nervous system tumour conditions. She earned her PhD from the Institute for Neuroscience at University of Texas (UT), Austin in 2007 studying the multi-generational effects of endocrine disrupting pollutants on female health. She subsequently completed a post-doctoral fellowship at the Center for Strategic and Innovative Technologies at UT, Austin, investigating the effects of sleep deprivation on cognition and physical performance. Dr Brown completed her MD at UT Southwestern in Dallas, TX, in 2013, where she studied NF1. She subsequently completed a neurology residency at Mount Sinai and a neuro-oncology fellowship at Memorial Sloan Kettering Cancer Center, specializing in NF1. She developed and served as the director of the NF and SWN clinic at Mount Sinai before being recruited to UAB. Dr Brown’s primary research interest is the development of novel pharmacotherapies for NF and SWN-related tumours.

Dr Rebecca Brown discloses: Independent contractor fees from Pasithea, Inc. Advisory Board or panel fees from Neurovigil. Consultancy fees from Guidepoint.

Dr AeRang Kim

Dr Kaleb Yohay

Dr Kaleb Yohay

NYU Langone Health, New York, NY, USA
More Information
Close Popup

Dr Kaleb Yohay

NYU Langone Health, New York, NY, USA

Biography

Dr Kaleb Yohay, MD, is professor of neurology and paediatrics (clinical) at New York University (NYU) and director of the Division of Child Neurology and the Comprehensive Neurofibromatosis Center, which is recognized as recognized as one of the nation’s foremost for neurofibromatosis.

read more

Dr Yohay received his medical degree from the University of Vermont in 1993, and completed a residency in paediatrics and neurology at Johns Hopkins Hospital in Baltimore, MD. During his tenure at Johns Hopkins, he established and directed the Johns Hopkins Neurofibromatosis Center. He moved home to New York City in 2007, and joined the faculty at Weill Cornell Medical Center, and served as attending physician at New York Presbyterian and Memorial Sloan Kettering Cancer Center. Since 2014, Dr Yohay has been on the faculty at NYU Grossman School of Medicine.

Dr Yohay’s clinical practice is exclusively focused on treating individuals with NF1, NF2, and schwannomatosis. He is keenly invested in the development of best practice for the screening, treatment, and provision of age-appropriate guidance for those affected by neurofibromatosis. Dr Yohay has dedicated his career to pioneering new treatments for neuro-oncological and neuro-genetic conditions. This includes spearheading a gene therapy trial aimed at treating late infantile neuronal ceroid lipofuscinosis, innovating drug delivery techniques for pontine glioma, and leading clinical trials focused on neurofibromatosis. He is currently involved in national and international clinical trial consortia for NF1, NF2 and schwannomatosis. He serves as the chair of the programmatic panel for the Department of Defense Neurofibromatosis Research Program. Beyond his research interests, Dr Yohay is committed to the development and education of future NF-focused clinicians.

Dr Kaleb Yohay discloses: Advisory board or panel fees from Alexion. Stock/shareholder (self-managed) with Infixion Bioscience.

Dr Rebecca Brown

Prof. Allan Belzberg

Prof. Allan Belzberg

Johns Hopkins Medicine, Baltimore, MD, USA
More Information
Close Popup

Prof. Allan Belzberg

Johns Hopkins Medicine, Baltimore, MD, USA

Biography

Prof. Allan Belzberg is professor of Neurosurgery and Plastic & Reconstructive Surgery at the Johns Hopkins School of Medicine. He holds the George J. Heuer Chair in Neurosurgery and has a clinical focus on spine and peripheral nerve surgery. He is director of Peripheral Nerve Surgery at Johns Hopkins Hospital, Johns Hopkins All Children’s Hospital, and the Kennedy Krieger Institute.

read more

As a member of the multidisciplinary Comprehensive Neurofibromatosis Clinic at Johns Hopkins, Prof. Belzberg treats patients with a range of benign and malignant tumors. His clinical and research interests include neuropathic pain, and he is co-director of the Neurosurgery Pain Research Institute at Johns Hopkins. He has published extensively on the pathophysiology of painful nerves, including pain associated with neurofibromatosis and nerve injury. His laboratory developed a novel animal model of neuropathic pain that enables investigation of stimulus-evoked mechanical hyperalgesia and changes in pain phenotype in intact axons exposed to degenerating axons, as occurs in neuroma.

Prof. Belzberg also conducts basic science research on gene regulation in schwannomatosis and neural regeneration. He has served as president of the American Society for Peripheral Nerve, has lectured in more than 30 countries, and has published more than 175 peer-reviewed papers.

Prof. Allan Belzberg discloses: Speaker’s bureau fees from AstraZeneca (relationship terminated).

Dr Kaleb Yohay

Dr. Angela Hirbe

Dr. Angela Hirbe

Washington University, St Louis, MO, USA
More Information
Close Popup

Dr. Angela Hirbe

Washington University, St Louis, MO, USA

Biography

Dr. Angela Hirbe is associate professor of Medicine and Pediatrics in the Division of Oncology at Washington University School of Medicine. She is also director of the Adult Neurofibromatosis Clinical Program at the Washington University School of Medicine.

read more

Her clinical interests include the management of cancer predisposition syndromes, including neurofibromatosis-associated tumors, in pediatric and adult populations, as well as sarcomas. Dr. Hirbe has participated in clinical trials in neurofibromatosis type 1 (NF1), including benign and malignant peripheral nerve sheath tumors (MPNSTs). She leads a basic and translational laboratory focused on early cancer detection in NF1 and preclinical disease modeling. She has authored more than 150 peer-reviewed articles and abstracts.

Dr. Hirbe is vice chair of the National Comprehensive Cancer Network (NCCN) Bone Panel and a member of the Children’s Tumor Foundation and the SARC Career Development Committee. She also serves as co-chair of the Neurofibromatosis Clinical Trials Consortium MPNST Committee, is a member of the Children’s Oncology Group, and is an elected member of the American Society of Clinical Investigation.

Dr. Angela Hirbe discloses: Advisory board or panel fees from AstraZeneca and SpringWorks Therapeutics. Consultant fees from Aadi Bioscience (a subsidiary of Kaken Pharmaceutical), AstraZeneca/Alexion and SpringWorks Therapeutics. Grants/research support from Polaris Pharmaceuticals. Other financial or material support (royalties, patents, etc.) from Boehringer Ingelheim International (relationship terminated).

Prof. Allan Belzberg

Dr AeRang Kim

You Might Also Like9

touchONCOLOGY touchONCOLOGY

Register now for FREE access to

  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 10 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • Concise email updates and newsletters so you never miss out

These activities are funded by:

Independent medical education grants from Alexion and SpringWorks Therapeutics, Inc.

These activities are jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

The information provided by these CME activities is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

USF

USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

Artificial Intelligence

All content for these activities was developed and reviewed by human subject matter experts. The Accredited Provider may have used artificial intelligence-enabled tools to assist with administrative and data processing functions related to these activities. AI tools were not used to generate or make decisions about educational content.

This content is intended for healthcare professionals globally, excluding the UK.

Latest articles videos and clinical updates - straight to your inbox

Close Popup

What You'll Learn

After completing this Program, you'll be better able to:
Select Activity...
View All
Activity 1
Activity 2
Activity 1

Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life

Learning Objective 1

Formulate strategies to maximize outcomes and quality of life for patients with neurofibromatosis type 1 across all stages of life

Start Now
Learning Objective 2

Apply evidence-based practice to the management of neurofibromatosis type 1 and the treatment of plexiform neurofibromas in children and adults

Start Now
Learning Objective 3

Plan a coordinated transition from paediatric to adult healthcare for patients with neurofibromatosis type 1

Start Now
Activity 2

Management of NF1-related PNs: Approaches for delivering state-of-the-art care

Learning Objective 1

Explain the benefits and risks of systemic and targeted therapies based on the latest evidence for adults with NF1-PN within a multimodal care pathway

Start Now
Learning Objective 2

Describe approaches for monitoring response and managing adverse effects in adults receiving systemic or targeted treatment for NF1-PN

Start Now
Learning Objective 3

Evaluate pain, functional and quality-of-life outcomes to inform shared decision-making and multidisciplinary care plans for adults with NF1-PN

Start Now
Activity 1

Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life

Learning Objective 1

Formulate strategies to maximize outcomes and quality of life for patients with neurofibromatosis type 1 across all stages of life

Start Now
Learning Objective 2

Apply evidence-based practice to the management of neurofibromatosis type 1 and the treatment of plexiform neurofibromas in children and adults

Start Now
Learning Objective 3

Plan a coordinated transition from paediatric to adult healthcare for patients with neurofibromatosis type 1

Start Now
Activity 2

Management of NF1-related PNs: Approaches for delivering state-of-the-art care

Learning Objective 1

Explain the benefits and risks of systemic and targeted therapies based on the latest evidence for adults with NF1-PN within a multimodal care pathway

Start Now
Learning Objective 2

Describe approaches for monitoring response and managing adverse effects in adults receiving systemic or targeted treatment for NF1-PN

Start Now
Learning Objective 3

Evaluate pain, functional and quality-of-life outcomes to inform shared decision-making and multidisciplinary care plans for adults with NF1-PN

Start Now